A Trial of Varenicline for E-cigarette Cessation
Launched by YALE UNIVERSITY · Jun 18, 2025
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a medication called varenicline can help adults who regularly use e-cigarettes (vaping) to quit. The study is designed to compare varenicline with a placebo (a “dummy” pill) to see if the medicine makes it easier for people to stop using e-cigarettes.
Adults aged 18 to 74 who live in Connecticut or South Carolina and who use nicotine-containing e-cigarettes every day may be able to join the study. People who regularly use other tobacco products, are already receiving help to quit, have certain medical conditions that make varenicline unsafe, or do not speak English well would not be eligible. If you participate, you can expect to take medication and be part of a program aimed at helping you stop vaping, with support and monitoring from the study team. This trial is not yet recruiting participants but may offer a new option for those looking to quit e-cigarettes in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • report daily use of an e-cigarette containing nicotine
- • live in Connecticut or South Carolina
- Exclusion Criteria:
- • regular use of other tobacco products besides e-cigarettes
- • medical contraindications for varenicline use
- • current treatment for tobacco cessation
- • lack proficiency in English
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Charleston, South Carolina, United States
Patients applied
Trial Officials
Lisa Fucito, PhD
Principal Investigator
Yale University
Benjamin Toll, PhD
Principal Investigator
Medical University of South Carolina
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported